2024
Parallel electrophysiological abnormalities due to COVID‐19 infection and to Alzheimer's disease and related dementia
Jiang Y, Neal J, Sompol P, Yener G, Arakaki X, Norris C, Farina F, Ibanez A, Lopez S, Al‐Ezzi A, Kavcic V, Güntekin B, Babiloni C, Hajós M. Parallel electrophysiological abnormalities due to COVID‐19 infection and to Alzheimer's disease and related dementia. Alzheimer's & Dementia 2024, 20: 7296-7319. PMID: 39206795, PMCID: PMC11485397, DOI: 10.1002/alz.14089.Peer-Reviewed Original ResearchCOVID-19 patientsEEG abnormalitiesNeurophysiological abnormalitiesMild cognitive impairmentCognitive deficitsBrain activityAstrocyte reactivityPredicting long-term outcomesCognitive impairmentLong-term outcomesSlowing of EEGCognitive declineEfficacy of therapeutic interventionsIntrinsic brain activityLong COVIDElectrophysiological brain activityEEG slowingNeurological complicationsEpileptiform activityEEG monitoringEarly stages of neurodegenerative diseasesCognitive decline riskNeurovascular injuryLong COVID-19Acute phase
2006
Discovery of N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure−Activity Relationship
Wishka D, Walker D, Yates K, Reitz S, Jia S, Myers J, Olson K, Jacobsen E, Wolfe M, Groppi V, Hanchar A, Thornburgh B, Cortes-Burgos L, Wong E, Staton B, Raub T, Higdon N, Wall T, Hurst R, Walters R, Hoffmann W, Hajos M, Franklin S, Carey G, Gold L, Cook K, Sands S, Zhao S, Soglia J, Kalgutkar A, Arneric S, Rogers B. Discovery of N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure−Activity Relationship. Journal Of Medicinal Chemistry 2006, 49: 4425-4436. PMID: 16821801, DOI: 10.1021/jm0602413.Peer-Reviewed Original ResearchMeSH KeywordsAlpha7 Nicotinic Acetylcholine ReceptorAnimalsBiological AvailabilityBrainBridged Bicyclo Compounds, HeterocyclicCognition DisordersDrug StabilityEther-A-Go-Go Potassium ChannelsEvoked Potentials, AuditoryHumansIn Vitro TechniquesLearningMaleMemoryMicrosomes, LiverNeuronsNicotinic AgonistsNootropic AgentsPatch-Clamp TechniquesQuinuclidinesRadioligand AssayRatsRats, Sprague-DawleyReceptors, NicotinicRecognition, PsychologySchizophreniaStereoisomerismStructure-Activity RelationshipConceptsTreatment of cognitive deficitsPotential treatment of cognitive deficitsExcellent in vitro profileStructure-activity relationshipCognitive deficitsAlpha7 neuronal nicotinic acetylcholine receptorNicotinic acetylcholine receptorsCompound 14Novel object recognitionStructure-activityAuditory sensory gatingAssess cognitive performanceNeuronal nicotinic acetylcholine receptorsAlpha7 nAChR agonistAcetylcholine receptorsSensory gatingCognitive performanceNAChR agonistsPotential treatmentCompoundsAlpha7 nAChRsObject recognitionHigh oral bioavailabilitySchizophreniaBrain penetration